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A 49-year-old man presented with chest pain, dyspnea, and lactic acidosis. Left ventricular hypertrophy and myocardial
fibrosis were detected. The sequencing of mitochondrial genome (mtDNA) revealed the presence of A to G mtDNA point
mutation at position 3243 (m.3243A>G) in 𝑡𝑅𝑁𝐴Leu(UUR) gene. Diagnosis of cardiac involvement in a patient with Mitochondrial
Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes syndrome (MELAS) was made. Due to increased risk of sudden
cardiac death, cardioverter defibrillator was implanted.
1. Introduction
Mitochondrial disease is a multisystem disorder with highly
heterogeneous clinical pictures and can present at any age
[1]. The disorder may affect virtually any organ and cause
significant morbidity. The prevalence of mtDNA disease
is estimated at 1 : 5000 individuals in Western popula-
tions, and 1 : 200 of healthy newborns harbour a potentially
pathogenic mtDNA mutation [1]. The m.3243A>G mutation
in the MTTL1 gene (𝑡𝑅𝑁𝐴Leu(UUR)) is one of the com-
monest mtDNA mutations and can cause several clinical
phenotypes including, such as in the presented case, Mito-
chondrial Encephalomyopathy, Lactic Acidosis, and Stroke-
like episodes syndrome (MELAS) [2–4]. Other common
symptoms include seizures, cognitive impairment, muscle
weakness and exercise intolerance, sensorineural hearing
loss, cardiomyopathy, migraine, bowel dysmotility, and short
stature [4]. According to a recent retrospective study, hearing
loss and diabetes were the most frequent clinical features,
followed by stroke-like episodes [4]. In this context, genetic
counseling is an important component of patient diagnosis
[4].
2. Case Report
A 49-year-old man presented at emergency roomwith severe
chest pain, dyspnea, and metabolic decompensation with
lactic acidosis. Personal medical history was also charac-
terized by mild developmental delay, short stature, hear-
ing loss, renal and glycometabolic failure, lactic acidosis,
and a family history of sudden death in two maternal
relatives. Serial Troponin I was elevated and reached a
peak value of 6.8 ucg/L. Laboratory examinations revealed
also a significantly increased BNP value (808 ng/L, normal
value < 110 ng/L) and glucose level (852mg/dL, normal value
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Figure 1: (a) Electrocardiogram showing short PR interval and left ventricular (LV) hypertrophy. (b) Echocardiogram showing concentric,
nonobstructive LV hypertrophy.
< 110mg/dL) and a moderate increase in creatinine level
(2.3mg/dL, normal value < 1.3mg/dL) and lactate value
(2.2mmol/L, normal value < 1.6mmol/L). Electrocardio-
gram (ECG) revealed short PR interval and left ventricular
(LV) hypertrophy (Figure 1(a)). Echocardiogram showed
concentric, nonobstructive LV hypertrophy (Figure 1(b))
with ejection fraction (EF) of 55%, mild aortic and mitral
regurgitation, interatrial defect with left to right shunt, and
restrictive filling pattern. Urgent cardiac-CT using a second-
generation dual-source 128 slices CT scanner (Somatom
Definition Flash, Siemens, Erlangen, Germany) revealed
the presence of predominantly noncalcified atherosclerotic
plaques without significant obstructive coronary stenosis
and a severe concentric LV hypertrophy with preserved
global systolic function. The global LV myocardial mass was
increased to 186 gr/m2 (reference range: 70–113 gr/m2) with a
maximum wall thickness at the anterior basal wall of 20mm.
A small pericardial effusion and a mild hypertrophy of the
right ventricle with a maximum wall thickness of 8mm were
demonstrated. After 8 minutes, a late-enhancement acquisi-
tion using the dual-energy technique (100/140 kV setting)was
performed, showing multifocal areas of late-enhancement
(Figures 2(a1)–2(a6) color-coded maps; and Figures 2(b1)–
2(b6) merged gray-scale maps, arrows) with a nonischemic
pattern (subepicardial and predominantly intramural). Con-
sidering the information obtained by clinical history, labora-
tory testing, and imaging, the patient underwent thorough
genetic assessment due to a high index of suspicion for a
mitochondrial disorder. A cerebral CT performed as part
of the diagnostic work-up, showed atrophy of the cerebellar
vermis, basal ganglia calcifications, and focal white matter
hypodense lesions consistent with lacunar infarcts. A cardiac
Magnetic Resonance Imaging (MRI) study was performed
(1.5 T, Aera, Siemens Medical Systems, Erlangen, Germany)
after 2-week follow-up of supportive medical therapy show-
ingmultifocal areas of myocardial edema on T2-STIR images
with a nonischemic distribution (Figures 2(c1)–2(c6), arrows)
and a persistent but reduced LV hypertrophy, accounting for
a global myocardial mass of 155 gr/m2 with a maximum wall
thickness at the anterior basal wall of 15.5mm; the global
LV systolic function was still preserved. Multifocal patchy
late-enhancement concerning the presence of nonischemic
necrosis/fibrosis was demonstrated too (Figures 2(d1)–2(d6),
arrows), which correlated with late-enhancement detected by
Dual-Energy CT. 48-hour ECG monitoring was performed
and neither atrial nor ventricular arrhythmia were detected.
However, after considering the increased risk of sudden
cardiac death due to the strong family history and the
evidence of myocardial fibrosis, primary prophylaxis with
implantable cardioverter defibrillator (ICD) was performed.
After a lengthy hospital stay with supportive care, the patient
was later discharged from the hospital to home asymptomatic
and without further complications. During hospitalization
and at discharge, the patient did not present with any neu-
rological disturbances requiring antiepileptic medications,
antioxidants, and other cofactors [5]. The sequencing of
the whole mitochondrial genome (mtDNA) revealed the
presence of the A to G mitochondrial DNA (mtDNA) point
mutation at position 3243 (m.3243A>G) in 𝑡𝑅𝑁𝐴Leu(UUR)
gene (Figure 2(e), arrow), with variable mutant load in all the
analyzed tissues (Figure 2(f)).
3. Discussion
Since muscle contraction and relaxation are active processes
which involve energy metabolism and mitochondrial func-
tion, an impaired oxidative phosphorylation may in result in
cardiac dysfunction. Although the evidence from literature is
limited, a recent prospective study demonstrated the presence
of LV hypertrophy assessed by echocardiography in 2 of 8
adult patients with MELAS syndrome [6]. Nevertheless, car-
diac manifestation (arrhythmias, dilated or hypertrophic car-
diomyopathy) was reported to occur in about 38% of patients
with MELAS syndrome [7]. To the best of our knowledge,
this is the first case of a comprehensive integrated imaging
with both CT and MRI in a MELAS syndrome patient with
hypertrophic cardiomyopathy. Importantly, cardiac-CT can
be useful to exclude obstructive coronary artery disease in
the acute evaluation of chest pain patients presenting with
normal or low-positive troponin-elevation [8]. According to
a recent study [9], the presence of a concentric hypertrophic
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Figure 2: Color-coded (a1–a6) and merged gray-scale (b1–b6) late-enhancement Dual-Energy CT perfusion maps in four-chamber (a1, b1),
two-chamber (a2, b2), and short-axis views from base to apex (a3–a6 and b3–b6, resp.) showing the left ventricular (LV) hypertrophy and
diffuse, patchy, nonischemic (predominantly intramural), late-enhancement (arrows). T2-STIRMRI imaging (c1–c6) and phase sensitive T1-
weighted inversion recovery late-enhancement MRI images (d1–d6) in four-chamber (c1, d1), two-chamber (c2, d2), and short-axis views
from base to apex (c3–c6 and d3–d6, resp.) demonstrated diffuse, patchy, nonischemic (predominantly intramural) myocardial edema and
late-enhancement consistent with necrosis/fibrosis with a high level of concordance with Dual-Energy CT. (e) Sequence chromatograph of
the 𝑡𝑅𝑁𝐴Leu(UUR) region flanking the m.3243A>G mutation (arrow) in blood sample from the proband and in a wild type sample (Ctr). (f)
PCR-Restriction Fragment Length Polymorphism analysis showed the variable mutant load in patient’s peripheral tissues. B: blood; U: urine;
H: hair; S: saliva.
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remodelling pattern is frequently found in MELAS-like
patients. Furthermore, late gadolinium enhancement (LGE)
at MRI, which reflects expansion of the myocardial intersti-
tium caused by disperse interstitial fibrosis, partial myocar-
dial disarray, and fibrous replacement of irreversibly injured
myocytes, was present in 73% of patients (𝑛 = 8/11) with
a diffuse, nonischemic (predominantly intramural), patchy
pattern [9], such as in the presented case. Another interesting
mechanism involved in the development of the LGE pattern
observed in MELAS patients might be vessels leakage due to
mitochondrial angiopathy, such as for stroke-like lesions [9].
The vasogenic effect translates into changes in microvascular
permeability and extracellular edema formation that may in
part contribute to the myocardial LGE [9]. That is in accor-
dance with the presence of multifocal edema at the T2-STIR
sequences [9]. In the current case, the reduction of myocar-
dial mass of approximately 17% observed between cardiac-
CT and cardiac-MRI was supposed to be related primarily
to myocardial edema regression after supportive medical
therapy, although different techniques and software appli-
cations between the two methods may in part explain that
discrepancy.
Myocardial viability imaging by delayed-enhancement
Dual-Energy CT is a recently introduced and promising
technique that takes advantage of the fact that iodine, the
typically used contrast material in CT, shows similar washout
kinetics of gadolinium and has a very unique dual-energy
absorption characteristic at different X-ray spectra. In this
way, by generating color-coded perfusion map of iodine
distribution, it is possible to enhance contrast resolution
of CT imaging to achieve a better detection of iodine
concentration within myocardial fibrotic scar [10]. This has
allowed imaging of infarctedmyocardiumwith a high level of
concordance between CT andMRI. Similarly to other genetic
cardiomyopathies (including hypertrophic cardiomiopathy),
LGE detection may play an additional prognostic role in the
risk stratification of MELAS patients since LGE has been
related to worsening of LV function and adverse outcome
[9, 11].
The current study highlights the importance of multi-
modality imaging with echocardiography, cardiac-CT, and
cardiac-MRI if there is any suspicion of cardiac involvement
associated with a rare neurometabolic disorder. In such cases,
integrated information derived by CT and MRI regarding
the presence and distribution of coronary atherosclerosis,
myocardial edema, and late-enhancement may have impor-
tant therapeutic and prognostic consequences.
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